Long-acting intestinal hormone polypeptide analog and application for treating type 2 diabetes

A technology of analogs and drugs, applied in the field of pharmaceuticals, can solve the problems of short half-life of liraglutide, inconvenient clinical use, and failure to meet clinical standards, and achieve the effect of facilitating clinical promotion and application and prolonging the half-life

Inactive Publication Date: 2016-08-24
HEFEI TIANHUI BIOTECH CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the serum half-life of GLP-1(7-37) is only 3-5 minutes, and multiple injections per day are very inconvenient in clinical use
[0003] At present, many studies have used GLP-1 analog fusion protein technology to solve the retention time of GLP-1 analogs in the body. However, the existing technology is still far from the ideal clinical goal, and generally has not yet reached the clinical goal. Standard, Liraglutide recently produced by Novo Norisk is a GLP-1 analogue, which modifies GLP-1 with palmitic acid, and was launched in the United States in 2009
However, liraglutide also has the problem of short half-life, and its dosage form still needs daily injections

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Long-acting intestinal hormone polypeptide analog and application for treating type 2 diabetes
  • Long-acting intestinal hormone polypeptide analog and application for treating type 2 diabetes
  • Long-acting intestinal hormone polypeptide analog and application for treating type 2 diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Embodiment 1: the solid-phase synthesis of polypeptide

[0040] Using the solid-phase polypeptide synthesis method of the Fmoc strategy, the CS336X instrument produced by CSBio Company was used to synthesize the polypeptide of the present invention. The method of synthesis was carried out according to the manufacturer's instruction manual. The "Fmoc strategy" described herein refers to a synthetic method for synthesizing polypeptides by sequentially condensing amino-terminal Fmoc-protected amino acids in the presence of coupling reagents using polymer resin as a solid-phase reaction substrate. For its specific method, see Fmoc solid phase peptide synthesis: a practical approach, 2000, Oxford University Press.

[0041] The prepared polypeptide was purified using HPLC C18 semi-preparative column, and the mobile phase was acetonitrile. The polypeptide freeze-dried powder is obtained by desalting and freeze-drying. The polypeptides included in the patent of the present inv...

Embodiment 2

[0042] Example 2: Hypoglycemic Function of GLP-1 Analogs

[0043] In this embodiment, the polypeptides used are as follows:

[0044] SEQ ID NO 4: HAEGTFTSDVSSYLEGQAAKEFIAWLCKGRGGC—aminocaproic acid;

[0045] SEQ ID NO 5: HAEGTFTSDVSSYLEGQAAK EFIAWLVKCRGAAC—amino caprylic acid;

[0046] SEQ ID NO 6: HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRCVVVVVC—aminodecanoic acid

[0047] Dissolve 1 mg of each of the above polypeptides in 1 ml of normal saline to make a polypeptide solution, and inject the polypeptide solution subcutaneously into mice (200 μl / mouse, 6 mice / group, purchased from the Shanghai Experimental Animal Center of the Chinese Academy of Sciences). After 30 minutes of administration, 400 Micrograms of glucose were injected into each mouse. The blood glucose of the mice was measured at 2 hours, 24 hours, 48 ​​hours, 72 hours and 96 hours after the glucose injection (note: the same dose of glucose was given again two hours before each blood glucose measurement), and the results w...

Embodiment 3

[0049] Example 3: Stability determination of GLP-1 analogs in human serum

[0050] In this embodiment, the polypeptides used are as follows:

[0051] SEQ ID NO 4: HAEGTFTSDVSSYLEGQAAKEFIAWLCKGRGGC—aminocaproic acid;

[0052] SEQ ID NO 5: HAEGTFTSDVSSYLEGQAAK EFIAWLVKCRGAAC—amino caprylic acid;

[0053] SEQ ID NO 6: HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRCVVVVVC—aminodecanoic acid

[0054] (1) Serum preparation: Three blood samples were taken from volunteers with a vacuum blood collection needle (BD Biosciences, Franklin Lakes, NJ), and then immediately centrifuged at 13,000 rpm for 20 minutes on a centrifuge, and the upper layer of serum was taken for later use.

[0055] (2) Dissolve 0.1 mg of each of the above three polypeptides and GLP-1 standard (purchased from Shanghai Shenggong Company, its sequence is: HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG) in 0.5 ml of normal saline, and add to 1 ml of rat serum after fully dissolving ( Purchased from Invitrogen Company), the serum was marked as bl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided are a GLP-1 analogue and uses thereof. The GLP-1 analogue has the following general formula: HAEGTFTSDVSSYLEGQAAKEFIAWLX27KX29RX31n1YCZ, wherein X27 is valine or cysteine, X29 is glycine or cysteine, X31 is glycine or cysteine, and at least one of X27, X29 and X31 is cysteine; n1Y represents n1 Ys, n1=1-10, and Y is glycine, alanine or valine; Z represents amino saturated fatty acid; and two cysteines contained in the general formula both form disulfide bonds. The GLP-1 analogue of the present invention can effectively increase the blood half-life period of GLP-1 and can be used for treating diabetes and adiposis.

Description

technical field [0001] The invention relates to the field of pharmaceutical technology, in particular to a GLP-1 analogue and its application in the preparation of medicines for diabetes, obesity and / or diabetes, obesity-related diseases and obesity prevention. Background technique [0002] GLP-1 (glucagon-likepeptide-1, hereinafter referred to as: GLP-1) involved in the present invention is a polypeptide composed of 37 amino acids mainly secreted by small intestinal L cells, and its active form is GLP-1(7-37) OH and GLP-1(7-36)NH2 (Mojsov S, J Clin Invest. 1987 Feb;79(2):616-9). GLP-1 significantly reduces blood sugar after meals, can stimulate the production of insulin, and can also achieve a certain weight loss effect, and will not cause hypoglycemia (Drucker D J, Diabetes.1998Feb; 47(2): 159-69) . Recent studies have also shown that GLP-1 has a role in pancreatic regeneration (Drucker D J, 2003Dec; 144(12):5145-8). In addition, because GLP-1 is a fully humanized polyp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/605A61K38/26A61P3/10A61P3/04
CPCA61K38/26C07K14/605
Inventor 李瑛高井珍伊原
Owner HEFEI TIANHUI BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap